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(57) ABSTRACT
Problems with transience of siRNA-mediated knock-down 
and transfection efficiency have limited the scope o f RNAi- 
based experiments. The invention provides a tool for 
employing RNAi more efficiently and effectively by inte­
grating RNAi expression with methods of cell enrichment.
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M E T H O D  F O R  O B T A IN IN G  A N  E N R IC H E D  
P O P U L A T IO N  O F  S IR N A -E X P R E S S IN G  C E L L S
CROSS-REFERENCE TO RELATED
APPLICATIONS
[0001] This application is a continuation o f PCT Interna­
tional Patent Application No. PCT/US2004/041714, filed on 
Dec. 10, 2004, designating the United States o f America, 
and published, in English, as PCT International Publication 
No. WO 2005/059102 A3 on Jun. 30, 2005, which applica­
tion claims priority to U.S. Provisional Patent Application 
Ser. No. 60/528,567, filed on Dec. 10, 2003, the contents o f  
the entirety o f each o f which are incorporated herein by this 
reference. This application also claims the benefit o f the 
previously identified U.S. Provisional Patent Application 
No. 60/528,567 filed Dec. 10, 2003.
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT
[0002] This research o f the present invention was sup­
ported in part by the National Institutes o f Health 
(AI054188). The US government may have rights in this 
invention.
TECHNICAL FIELD
[0003] The invention relates to biotechnology generally 
and, more particularly, to enrichment o f double-stranded 
RNA expression.
BACKGROUND
[0004] The ability to specifically down-regulate gene 
expression is a powerful means o f gene function analysis in 
many model systems. Until recently, the only available 
method o f targeted gene down-regulation in mammalian 
systems has been expensive and cumbersome gene knockout 
technology in mice. However, the characterization o f RNA 
interference (RNAi) in C. elegans and plants led to the 
discovery of a similar system in mammalian cells. RNAi is 
the phenomenon by which double-stranded, small interfer­
ing RNAs (siRNAs) target the cognate mRNA for degrada­
tion by the RNA Induced Silencing Complex (RISC), thus 
suppressing gene expression at the translational level (G. J. 
Harmon (2002), RNA interference, Nature 418(6894):244- 
51).
[0005] However, there are several limitations to effec­
tively applying RNAi technology in mammalian systems. 
First, mammalian cells lack the RNA-dependent RNA poly­
merase, present in C. elegans and plants, which facilitates 
amplification and sustained expression o f the interfering 
RNA signal (P. J. Paddison and G. J. Harmon (2002), RNA 
interference: the new somatic cell genetics?, Cancer Cell 
2(1): 17-23 (hereinafter Paddison 2002); and Hannon 2002). 
Because o f this, the effect o f transfected siRNAs in mam­
malian cells is transient, restricting the temporal window 
available for gene function analysis. The development of  
polIII promoter-based expression vectors that express short 
hairpin RNAs (shRNAs) resembling double-stranded siR­
NAs may be used to overcome siRNA transience (Brum- 
melkamp et al. (2002), A  system for stable expression of  
short interfering RNAs in mammalian cells, Science 
296(5567):550-3). Such vectors allow for a sustained RNAi 
effect by transient or stable transfection o f the vector pro­
ducing the RNAi effect. However, this approach is limited 
by transfection efficiency variability in different cell culture 
conditions or cell types.
[0006] In addition to transfection, a library of siRNA 
molecules may be introduced into the appropriate host cells 
using a viral approach. For example, lentiviral vectors may 
be used. However, the construction and preparation o f a 
library o f viral vectors requires a major investment in time 
and money. In addition, it is also possible that the viral 
vector itself will modulate a cellular response that may be 
undesirable. Finally, viral based vectors, e.g., retrovirus- 
based vectors, cannot be used for the stable expression o f 
siRNAs in all cell types, this would require the added time 
and expense o f moving siRNA-encoding inserts to different 
vectors.
[0007] The present invention overcomes these limitations 
and provides compositions and methods that, for example, 
may save significant amounts o f both time and money.
SUMMARY OF THE INVENTION
[0008] The invention provides a technique to circumvent 
the limitations o f transfection efficiency while retaining 
desirable sustained RNAi expression. The invention relates 
to a method o f obtaining cells capable o f expressing inhibi­
tory RNA by introducing at least one nucleic acid into a cell, 
wherein the at least one nucleic acid is capable o f expressing 
an RNAi molecule and a separation marker; expressing the 
separation marker; sorting the cell based on expression o f 
the separation marker; and expressing the RNAi molecule in 
an amount sufficient to inhibit expression o f the target gene.
[0009] The invention also relates to targeting cellular, 
exogenous, viral and transgenes for RNA inhibition. In one 
embodiment, the invention relates to transfection o f mam­
malian cells while retaining desirable sustained RNAi 
expression.
[0010] The invention further relates to sorting cells based 
on expression o f a separation marker. Exemplary embodi­
ments include sorting by fluorescence activated cell sorting 
and magnetic cell separation.
[0011] The invention also relates to a method o f enriching 
a population o f mammalian cells having an RNAi sequence 
by providing eukaryotic, e.g., mammalian, cells containing 
a taiget gene, into which a construct capable o f expressing 
an RNA and a separation marker are introduced, wherein the 
RNA contains a double-stranded region o f the molecule with 
a first region having a sequence which corresponds to a 
nucleotide sequence o f the taiget gene and a second region 
having a sequence which is complementary to the first 
region, wherein the first and the second regions o f the RNA 
hybridize to each other to form a double-stranded RNA 
molecule; expressing the separation marker, wherein expres­
sion o f the separation marker is indicative o f the presence o f 
the double-stranded RNA molecule; and sorting the eukary­
otic cells expressing the separation marker, thereby enrich­
ing for the eukaryotic cells having the double-stranded RNA 
sequence.
[0012] The invention also relates to one or more recom­
binant nucleic acids having a separation marker and a 
promoter operably linked to a nucleotide sequence having a 
sequence which is complementary to a target gene product. 
In an exemplary embodiment, the nucleotide sequence com­
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prises a first region which is complementary to the target 
gene product and a second region which is complementary 
to the first region.
[0013] In an exemplary embodiment, the recombinant 
nucleic acid is a vector or expression vector. One exemplary 
embodiment o f an expression vector is pHYPER.
[0014] In another exemplary embodiment, the invention 
relates to a library o f siRNA sequences, wherein the library 
may be random sequences or a related set o f sequences. In 
another exemplary embodiment, the invention relates to a 
method o f preparing and/or enriching cells transfected with 
a library of related siRNA sequences or a random set o f  
siRNA sequences. In another exemplary embodiment, the 
invention provides the ability to enrich the population trans­
fected with a library o f siRNA sequences.
[0015] In another exemplary embodiment, the invention 
relates to a recombinant nucleic acid, comprising a nucleic 
acid having a first region including one or more unknown 
nucleotide positions, a second region capable o f forming a 
loop and a third region comprising the complement o f the 
one or more unknown nucleotide positions, wherein the 
nucleic acid is capable o f forming a stem-loop structure.
[0016] The invention further relates to a recombinant 
nucleic acid comprising at least one nucleic acid having a 
means for producing a separation marker and a means for 
producing a ribonucleotide sequence which is complemen­
tary to a target gene product.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] FIG. 1 is a map o f the pMACS-K/k-Hl-Radl7 
plasmid showing the shRNA sequence (SEQ ID NO: 1 being 
the top strand and SEQ ID NO:2 being the complement to 
the bottom strand).
[0018] FIGS. 2A, B, and D illustrate that transfection 
efficiencies o f 49% and 42% were achieved for pMACS-K/ 
k-Hl andpMACS-K/k-Hl-Radl7, respectively compared to 
HeLa control as indicated by a-K/k.II-FITC binding. FIGS. 
2C and E illustrate that cell populations were enriched to 
purities o f 97% and 98% for pMACS-K/k-Hl and pMACS- 
K/k-Hl-Radl7, respectively.
[0019] FIG. 3 shows that Radl7 protein levels are sig­
nificantly reduced in pMACS-K/k-Hl-Radl7 expressing 
cells relative to those expressing no RNAi (pMACS-K/k- 
H l) at least 72 hours post-transfection.
[0020] FIG. 4 illustrates a method o f constructing a 
library o f RNAi sequences in a plasmid o f the invention 
utilizing Cre/Lox recombination to transfer a library of  
sequences from one source to another.
DETAILED DESCRIPTION OF THE 
INVENTION
[0021] Problems with the transience o f siRNA-mediated 
knock-down and transfection efficiency, for example, trans­
fection o f polIII-based RNAi expression vectors, have lim­
ited the scope of RNAi-based experiments, for example, in 
mammalian-based model systems. The invention provides a 
tool for employing RNAi more efficiently and effectively by 
integrating RNAi expression with methods o f cell enrich­
ment. In an exemplary embodiment, the invention provides 
a method o f isolating a population of cells, for example, at
least 97% pure, for expression o f the pMACS-K/k-Hl- 
Radl7 plasmid (FIG. 2). Furthermore, expression o f shRNA 
from this plasmid can suppress expression o f a mammalian 
gene product, and this inhibition can be maintained for at 
least 72 hours after transfection o f the pMACS-K/k-Hl- 
Radl7 plasmid (FIG. 3). Thus, the invention demonstrates 
the successful application o f cell separation, for example, 
pMACS-K/k-Hl, as a means of enriching a population for 
the presence o f RNAi.
[0022] Two groups, P. J. Paddison et al. (2004), A  
Resource for Large-scale RNA-interference-based Screens 
in Mammals, Nature 428:427-431, and K. Bems et al. 
(2004), A  Large-scale RNAi Screen in Human Cells Iden­
tifies New Components o f the p53 Pathway, Nature 
428:431-437 (see also Andrew Fraser (2004), RNA Inter­
ference: Human Genes Hit the Big Screen, Nature 428:375­
378), have utilized a retroviral vector to conduct large-scale 
screening, e.g., genome-wide. However, both groups have 
utilized retroviral vectors and such vectors have a number of 
disadvantages that are overcome by the present invention.
[0023] shRNAs often inhibit or knock-down target genes 
to differing extents, hence multiple, e.g., greater than two, 
three, or four shRNAs may be generated for each gene. Such 
multiple coverage may provide an internal control, and/or 
allow comparison of knock-downs having differing 
strengths, e.g., strong and weak, allowing analysis compa­
rable to classical genetic approaches.
[0024] RNA interference may be produced by an number 
o f different RNA inhibitors, as used herein “RNA inhibitor, 
’’“inhibiting RNA” and similar phrases mean RNA 
sequences capable o f producing an effect referred to as RNA 
interference, which is believed to result from the sequence- 
specific cleavage of mRNAs, preventing translation o f func­
tional gene products, inhibiting RNAs include, shRNA, 
siRNA, dsRNA and other RNAi products.
[0025] The invention relates to a population o f cells that 
may be enriched for production o f an siRNA. A person o f 
skill in the art may, for example, test or analyze several 
target sequences in order to optimize the knock-down effect 
or compare the effects. Additionally, a person o f skill in the 
art may modulate knock-down efficacy due to such factors 
as target mRNA abundance, expression level, turnover rate 
and/or by protein half-life (Elbashir et al. (2001), Duplexes 
o f 21-nucleotide RNAs mediate RNA interference in cul­
tured mammalian cells, Nature 411(6836):494-8).
[0026] The pMACS-K/k-Hl system o f RNA interference 
can be applied as a means or method o f studying suppression 
o f gene function, for example, in mammalian cells. This 
technique may be useful for RNA interference in cell lines 
that are difficult to transfect. With a very minimal level o f 
transfection, one can isolate a highly enriched population o f 
shRNA-expressing cells. Additionally, the method facilitates 
experiments requiring an extended period of gene suppres­
sion.
[0027] The pMACS-K/k-Hl system o f RNAi delivery is 
an improvement on the current technology that may expand 
the ability to perform RNAi-based experiments. Further, 
cells separated based on expression o f shRNA or other 
RNAi, may be useful for treatment o f disease, for example, 
by ex vivo gene therapy. The methods of the invention may 
be used with any cell, including, but not limited to, eukary­
otic cells such as mammalian cells or plant cells.
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[0028] In an exemplary embodiment, the invention pro­
vides a technique to circumvent the limitations o f transfec­
tion efficiency while retaining the desirable sustained RNAi 
expression of a polIII vector-based system. By cloning the 
polIII HI promoter into a pMACS-K/k.II plasmid (Miltenyi 
Biotech, Cologne, Germany) for transfected cell separation, 
cell populations 98% positive for shRNA expression were 
reproducibly isolated. Using this system, significant knock­
down o f a mammalian gene expression was demonstrated, 
up to 72 hours after RNAi-expressing plasmid transfection. 
Thus, this system facilitates more consistent, sustained and 
enhanced RNA interference. Furthermore, it is now possible 
to perform effective RNAi experiments in cell lines that have 
previously been difficult to transfect with either synthetic 
siRNA, shRNA or double-stranded expression vectors.
[0029] The invention provides a method wherein the 
RNAi inhibition signal is increased and/or the noise is 
decreased for a population o f cells. For example, transfec­
tion o f primary cells or lymphocytes may result in a trans­
fection efficiency o f less than about 5%. Thus, without 
selection the signal obtained from the RNAi knockout is 
likely to be overwhelmed by the noise from the non­
transfected cells. Using the methods and compositions o f the 
invention, a population o f cells may be transformed or 
transfected, selected to enrich for the transformed or trans­
fected cells and the selected cells assayed. Thereby remov­
ing the background from the non-transfected (non-trans- 
formed) cells. Thus, the invention allows RNAi studies in 
cells having a low transfection or transformation efficiency. 
For example, a transformation or transfection efficiency of  
less than 50%, less than 40%, less than 30%, less than 20% 
or less than 10% may benefit from the invention. For 
example, HeLa cells may have a transfection efficiency of  
approximately 30%. Using the method o f the invention the 
noise due to non-transfected cells may be reduced, thereby 
improving a downstream assay, such as, a phenotypic and/or 
genotypic analysis.
[0030] The reduction in noise due to non-transfected cells 
is particularly advantageous when screening and/or analyz­
ing a large number of constructs, such as a library o f siRNA 
constructs.
[0031] Sorting or enriching for transfected cells may be 
performed by fluorescence activated cell sorting (FACS) 
(Gross et al. (1995), Model Study Detecting Breast Cancer 
Cells in Peripheral Blood Mononuclear Cells at Frequencies 
as low as 10-7, Proc. Natl. Acad. Sci. USA), immuno-affinity 
cell separation techniques (Lebkowski et al. (1992), Rapid 
isolation o f CD34+ cells from PB o f autologous transplant 
patient, B lood  80 (suppl.) 1:527; and U.S. Pat. No. 5,912, 
177), affinity-based separation methods (for example, a 
streptavidin affinity column for a biotin label, magnetic 
microparticles coupled to antibodies (Shpall et al. (1991), 
B one M arrow  Transplantation  7:145) and High gradient 
magnetic cell sorting (Miltenyi et al. (1990), High Gradient 
Magnetic Cell Sorting with MACS, Cytom etry  11:231 -239), 
dielectrophoretic/gravitational field-flow fractionation and 
centrifugation. An overview o f cell separation techniques is 
provided by Cell Separation M ethods and Applications, 
Recktenwald et a l, eds. (1998). As will be recognized by a 
person o f ordinary skill in the art, cell sorting or enrichment 
may utilize separation markers that are recognized by anti­
bodies, photometric systems or the like, such as fluorescent 
molecules and chemiluminescent markers.
[0032] In an exemplary embodiment, separation antibod­
ies are coupled to a magnetic reagent, such as a paramag­
netic micro- or nano-particle (microparticle or nanoparticle). 
Magnetic cell separation is a means/method whereby taiget 
cells may be labeled with a magnetic marker and then 
selectively retained or excluded through exposure to a 
magnetic field. Examples o f such methods can be found in 
Kantor et al. (1998, Magnetic Cell Sorting with Colloidal 
Superparamagnetic Particles, in C ell Separation M ethods  
and Applications)', Gee (1998, Immunomagnetic Cell Sepa­
ration Using Antibodies and Superparamagnetic Micro­
spheres in C ell Separation M ethods and Applications)', and 
U.S. Pat. No. 5,411,863. For high gradient magnetic sepa­
ration, typically a heterogeneous suspension, containing 
selected cells bound to magnetic markers, is passed through 
a column, allowing cells having a magnetic marker to adhere 
magnetically to a column or a paramagnetic matrix within 
the column. The remainder o f the suspension is eluted, 
leaving the desired, magnetized cells bound to the column. 
When the magnetic field is removed, the bound cells can be 
eluted. U.S. Pat. No. 4,452,773 describes the preparation o f 
magnetic iron-dextran microparticles and provides a sum­
mary describing the various means of preparing particles 
suitable for attachment to biological materials. A  description 
o f polymeric coatings for magnetic particles may be found 
in DE 3720844 and U.S. Pat. No. 5,385,707. Methods to 
prepare superparamagnetic particles are described in U.S. 
Pat. No. 4,770,183. Magnetic cell separation includes, but is 
not limited to, diamagnetic, paramagnetic, ferromagnetic 
and superparamagnetic materials (see, U.S. Pat. No. 5,385, 
707). Thus, the invention includes magnetic separation using 
a range o f magnetic properties. The extent o f magnetization 
which is acquired by a particle is a function of magnetic 
moment, volume of the particle and the applied magnetic 
field. For example, the higher the magnetic moment and the 
smaller the volume, the higher the magnetization.
[0033] In another exemplary embodiment, separation 
markers or antibodies are, or are coupled to, a fluorochrome. 
The transfected or transformed population o f cells may then 
be sorted by fluorescence activated cell sorting. In yet 
another exemplary embodiment, the transfected or trans­
formed cells are sorted by a method commonly referred to 
as panning. For example, antibodies are coupled to a solid 
support and the transfected or transformed population is 
exposed to the antibodies on the solid support. Subsequently, 
unbound cells are removed by washing while the cells 
expressing the separation marker, which may be bound 
directly or indirectly by the attached antibodies, will remain 
bound to the solid support. The bound cells may then be 
eluted at the desired time.
[0034] Separation markers may be found on the cell 
surface (for example, the plasma membrane or cell wall), 
extracellular matrix, in the cytoplasm, cellular oiganelles, 
cellular oiganelle compartments or organelle membranes, 
such as the nuclear membrane, or extracellularly (see, 
United States Patent Application 20020182645). However, 
the separation marker preferably should be accessible to the 
sorting means or method without disruption of the cell. For 
example, green fluorescence protein (see U.S. Pat. No. 
6,319,669) or Beta galactosidase (e.g., using fluorescein 
digalactoside (FDG)) may be expressed from a vector, 
incorporated into the nuclear membrane, and the cells sorted 
by fluorescence-activated cell sorting (FACS) or flow 
cytometry (see Anderson et al. (1996), Proc. Natl. Acad. Sci.
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USA 93:8508-8511). In an exemplary embodiment, the 
separation marker is any molecule not expressed, or 
expressed at suitably low levels, in the cell population to be 
sorted, for example, one or more intercellular adhesion 
molecules (ICANs) or fragments thereof may be used. In yet 
another embodiment, a recombinant chimeric molecule may 
be used. For example, a fragment o f an IgG immunoglobulin 
(e.g., a mouse heavy chain or fragment thereof) may be 
fused to a cell surface protein. In another embodiment, the 
separation molecule may alter the size, shape or other 
properties o f a cell. For example, the separation marker may 
alter the forward and/or side scatter properties o f the cell. 
Thus, the separation markers o f the invention include any 
means or molecule capable o f identifying a cell carrying the 
RNAi construct.
[0035] The separation marker may act directly or indi­
rectly and may be detected directly or indirectly. A  person of  
ordinary skill in the art, using the guidance provided herein, 
will recognize that the particular separation marker or sepa­
ration method used is not crucial to the invention and may 
be any appropriate method and/or molecule, or fragment of  
a molecule, sufficient to identify the cell and allow separa­
tion from cells lacking the separation marker. A  separation 
marker may be combined with a selectable marker (for 
example, antibiotic resistance markers such as puromycin- 
resistance and ampicillin resistance). Separation markers 
differ from selection markers in that a separation marker 
does not require the application o f lethal drugs to the cells. 
Further, separation markers offer significantly more choices 
than does the use of selection markers. For example, mul­
tiple separation markers may be used and cells may be sorted 
into those having all markers or subsets o f the markers. 
Thus, significantly more flexibility is offered with separation 
markers. In addition, the presence of one or more selection 
markers has raised concerns that cells containing these 
markers (typically antibiotic resistance genes) could transfer 
the resistance to bacteria or other organisms, making anti­
biotic medicines less effective. In contrast, a separation 
marker may be used without such concern.
[0036] The exact method for detecting a separation marker 
is not critical to the practice o f the invention, and a number 
o f alternatives are known in the art. For example, separation 
antibodies may be directly coupled to detectable particles. 
Indirect coupling can be accomplished by several methods. 
The antibodies may be coupled to one member o f a high 
affinity binding system (e.g., biotin) and the particles 
attached to the other member (e.g., avidin). One may also 
use second stage antibodies that recognize species-specific 
epitopes of the antibodies, e.g. anti-mouse Ig, anti-rat Ig, etc. 
Indirect coupling methods allow the use o f a single mag­
netically coupled entity, e.g. antibody, avidin, magnetolipo- 
some, etc., with a variety o f separation antibodies.
[0037] In one embodiment, hapten-specific second stage 
antibodies coupled to detectable particles may be used (e.g., 
magnetic particles or fluorochromes). As used herein 
“detectable particles” include magnetic reagents and fluo­
rescent molecules. The hapten-specific antibodies may have 
an affinity o f at least about 100 (xM for the hapten. The 
antibodies may be conjugated to an appropriate hapten. 
Suitable haptens include digoxin, digoxigenin, FITC, dini- 
trophenyl, nitrophenyl, etc. Methods for conjugation o f a 
hapten or detectable particle to an antibody are known in the 
art.
[0038] Irnmuno-magnetic selection has been used to select 
cells expressing a marker, for example, a surface marker, 
transiently transfected cells containing a plasmid(s) encod­
ing a selectable marker, and after uptake and expression o f 
the plasmid(s), the transfected cells are immuno-adsorbed to 
antibody coated magnetic beads. In a single round o f mag­
netic selection, it is possible to enrich the cell population 
more than seven-fold in the case o f co-transfection. See 
Aileen Constans (2000), Field o f Dreams: Innovations in 
Magnetic Particle Technology Advance Many Fields, The 
Scientist 14(13):23; and Partington (1999), A  novel method 
o f cell separation based on dual parameter immunomagnetic 
cell selection, J. Immunol. Methods. 223(2): 195-205.
[0039] Antibodies o f the invention may include enzyme 
conjugated antibodies (e.g., horseradish peroxidase, phos­
phatase, etc.), haptenated antibodies (e.g., biotin conjugates, 
digoxigenin conjugates, etc.) or a fluorochrome conjugated 
antibody (e.g., phycoerythrin, FITC, rhodamine, Texas red, 
allophycocyanin, etc.). The antibodies may have specificity 
for any antigen useful in the separation o f a subpopulation. 
Reagents may also include blocking agents that reduce 
non-specific labeling (e.g., Fc receptor blocking reagent, 
peroxidase blocking reagent, etc.). For example, a cocktail 
o f digoxigenin-coupled antibodies may be used in combi­
nation with anti-digoxigenin antibody coupled to magnetic 
particles, which may be followed by labeling with a fluo­
rochrome conjugated antibody directed to the anti-hapten 
antibody.
[0040] A library of siRNA sequences, includes, but is not 
limited to, a library o f random sequences or a library o f 
related set o f sequences. A  related set o f sequences may 
comprise siRNA sequences capable o f inhibiting one or 
more members o f a gene family or subfamily, examples o f 
gene families and the methods to categorize genes into a 
family or subfamily are well known in the art. As will be 
recognized by a person o f ordinary skill in the art, gene 
families or subfamilies are common and the list o f such 
families is continually expanding. As an illustrative 
example, the 5-hydroxytryptamine (5-HT) receptor family is 
known to have at least seven subfamilies (S-H T ^). Using 
the present invention, it is possible to construct a library o f 
RNAi sequences, transfect a population o f cells with the 
library, enrich the population for those transfected with an 
RNAi sequence, and to screen the enriched population. The 
ability to enrich the transfected population provides advan­
tages when conducting screens using a library of random 
sequences (e.g., genome-wide screening) or a related set o f 
sequences (e.g., gene family screening and/or analysis, gene 
subfamily screening and/or analysis, screening and/or ana­
lyzing a protein class. As will be recognized by a person o f 
ordinary skill in the art, the ability to enrich the population 
may provide significant advantages where a large number o f 
constructs are to be introduced and screened and/or ana­
lyzed.
[0041] Transfection o f siRNA is a critical step in gene 
silencing experiments. A  difficulty encountered with all 
transfection techniques is the transfection efficiency. For 
example, if  a pool o f cells is transfected at less than 100% 
efficiency, which is almost always the case, any assay will 
become difficult to interpret or require significantly more 
time and/or reagents, all o f which increase the cost. As will 
be recognized by a person o f ordinary skill in the art, this 
aspect o f transfection drives the need for appropriate trans­
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fection efficiency controls. In another exemplary embodi­
ment, the invention relates to a method of preparing and/or 
enriching cells transfected with a library o f related siRNA 
sequences or a random set o f siRNA sequences. The library 
o f siRNA sequences may be produced by methods known in 
the art, for example, those described in Hutvagner et a l, A  
Cellular Function for the RNA-interference Enzyme Dicer 
in the Maturation o f the Let-7 Small Temporal RNA, Sci­
ence  293(5531):834-838; International Patent Publication 
WO 99/64582; International Patent Publication WO 
00/49035; International Patent Publication WO 96/29097; 
Pasquinelli et al. (2000), Conservation o f the Sequence and 
Temporal Expression o f Let-7 Heterochronic Regulatory 
RNA, N ature  408(6808);86-89; Yu Jenn-Yah et al. (2002), 
RNA Interference by Expression of Short-Interfering RNAs 
and hairpin RNAs in Mammalian Cells, Proc. Natl. Acad. 
Sci. USA 99(9):6047-6052; Raykov et al. (2002), Transient 
Suppression o f Transgene Expression by Means o f Anti­
sense Oligonucleotides: A  Method for the Production of  
Toxin-transducing Recombinant Viruses, Gene Therapy  
9(5):358-362; International Patent Publication WO 
03/020931 A2 to Gert-Jan Arts et al.; and Gert-Jan Arts et al.
(2003), Adenoviral Vectors Expressing siRNAs for Discov­
ery and Validation o f Gene Function, Genome Research  
13(10):2325-2332, which are incorporated by reference.
[0042] Screening and/or analysis o f a library o f siRNA 
molecules is typically done using a viral approach. However, 
such an approach is disadvantageous in that it requires a 
major investment in time to generate the virus stocks. This 
approach imposes additional costs in both time and direct 
costs (e.g., equipment and materials). In addition, care must 
be exercised that the use o f virus does not modulate a 
cellular response that is undesirable. Hence, care must be 
used in selecting the appropriate viral vector, and it may not 
be possible to effectively use a viral vector in some cases.
[0043] A  cell population may be cultured in media appro­
priate for the particular cells. To improve recovery, sorting 
by methods such as FACS may be performed using blank 
Hank’s media, or another appropriate media, as the sheath 
fluid. Samples to be sorted by methods such as FACS may 
be held in a rich medium that is most suitable to them. High 
serum concentrations may be advisable due to dilution in the 
collection vial by sheath fluid. The collection vials are 
typically maintained at the optimal temperature and contain 
media for preservation of cell viability. In addition, process­
ing o f the sorted cells as soon as possible after completion 
o f the sorting may help maintain cell viability.
[0044] In another embodiment, the cells o f the invention 
may be sorted multiple times. In particular, when the trans­
formation efficiency is low, for example, less than about 
10%, or the desired purity o f the sorted culture is high, for 
example, greater than 90%, the cells may be sorted two or 
more times. In another embodiment, the cells are separated 
using two or more separation markers in one or more sorting 
steps.
[0045] Dead cells may be excluded from the sorted popu­
lation by methods known in the art, for example, by addition 
(labeling) o f an appropriate amount o f propidium iodide (PI) 
or 7-aminoactinomycin D.
[0046] The inhibitory RNA molecule o f the invention may 
be o f any length appropriate and desirable for a particular 
purpose. For example, siRNA is typically about 18 to about
26 nucleotides in length, with length typically measured by 
the length o f the sequence complementary to the taiget 
sequence (e.g., the mRNA) (for example, see McCaffrey et 
al. (2003), Inhibition o f Hepatitis B Virus in Mice by RNA 
Interference, Nat. B iotechnol. 21(6): 639-644). Double­
stranded RNA may be from about 18 to thousands o f 
nucleotides in length. Double-stranded RNA is typically 
cleaved either in vitro or in vivo by an RNase, such as the 
RNase III referred to as “dicer,” to produce siRNAs (for 
example, see U.S. Pat. No. 6,506,559). However, longer 
double-stranded RNA molecules may trigger a dsRNA- 
activated protein kinase (PKR) response in a cell. PKR 
phosphorylates EIF-2a, which induces a generalized inhi­
bition o f translation. In addition, dsRNA may activate the 
2'5' oligoadenylate polymerase/RNase L system to repress 
IkB, leading to cell death via apoptosis. A person o f ordinary 
skill in the art may use methods known in the art to prevent 
or circumvent such a cellular response (e.g., using cells 
lacking a PKR response).
[0047] An shRNA may include a loop sequence o f 
between about four to about 26 nucleotides. The loop 
sequence need only be sufficiently long to allow the mol­
ecule to fold back on itself to produce the double-stranded 
“stem” structure (an intramolecular hybridization).
[0048] The double-stranded RNAi may comprise one or 
more strands o f polymerized ribonucleotide. The double­
stranded structure may be formed by one or more self- 
complementary or complementary RNA strands.
[0049] RNA containing a nucleotide sequences identical 
to a portion o f the taiget gene is typically preferred for 
inhibition. However, the invention has the advantage o f 
being able to tolerate sequence variations that might be 
expected due to genetic mutation, strain polymorphism, or 
evolutionary divergence. Therefore, insertions, deletions, 
and mutations, relative to the target sequence, are also 
effective for inhibition. The duplex region o f the RNA may 
be defined functionally as a nucleotide sequence that is 
capable o f hybridizing with a portion of the taiget gene 
transcript. Thus, a nucleotide sequence from a portion o f the 
target gene may be chosen to produce inhibitory RNA. 
RNAi is effective in producing inhibition of gene expression 
and may be used to inhibit many different types o f taiget 
genes (U.S. Pat. No. 6,506,559). As described herein, the 
RNAi sequence need not be 100% identical to the taiget 
gene to produce inhibition (Jackson et al. (2003), Expression 
profiling reveals off-target gene regulation by RNAi, Nat. 
Biotechnol. 21(6):635-637). For example, sequence differ­
ences at the 3' end o f the siRNA sense strand (5' end o f the 
antisense strand) relative to the target gene may still permit 
effective RNA inhibition.
[0050] Nucleic acid hybridization will be affected by such 
conditions as salt concentration, temperature, or organic 
solvents, in addition to the base composition, length o f the 
complementary strands, and the number o f nucleotide base 
mismatches between the hybridizing nucleic acids, as will 
be readily appreciated by those skilled in the art. Stringent 
temperature conditions will generally include temperatures 
in excess o f 30° C , typically in excess o f 37° C , and 
preferably in excess o f 45° C. Stringent salt conditions will 
ordinarily be less than 1000 mM, typically less than 500 
mM, and preferably less than 200 mM. However, the com­
bination o f parameters is much more important than the
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measure o f any single parameter. The stringency conditions 
are dependent on the length of the nucleic acid and the base 
composition o f the nucleic acid, and can be determined by 
techniques well known in the art, for example, Asubel, 1992; 
Wetmur and Davidson, 1968.
[0051] Thus, as herein used, the term “stringent condi­
tions” means hybridization will occur only if  there is at least 
80%, preferably at least 90%, more preferable 95% and most 
preferably at least 97% identity between the sequences. Such 
hybridization techniques are well known to those of skill in 
the art. Stringent hybridization conditions are as defined 
above or, alternatively, conditions under overnight incuba­
tion at 42° C. in a solution comprising: 50% formamide, 
5xSSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM 
sodium phosphate (pH7.6), 5x Denhardt’s solution, 10% 
dextran sulfate, and 20 (xg/ml denatured, sheared salmon 
sperm DNA, followed by washing the filters in O.lxSSC at 
about 65° C.
[0052] Methods o f attaching a nucleic acid to a membrane 
or support are well known in the art. For example, methods 
and representative membranes and supports may be found in 
Ausubel et a l, CURRENT PROTOCOLS IN MOLECU­
LAR BIOLOGY (John Wiley & Sons, Inc, 2004). In 
addition, screening assays, methods o f library preparation 
and other such methods and associated material are known 
in the art and may be found in Ausubel et al. Methods and 
materials relating to immunology, including antibodies and 
their use, may be found in Bierer et a l, CURRENT PRO­
TOCOLS IN IMMUNOLOGY (John Wiley & Sons, Inc, 
2004), and Harlow and Lane, ANTIBODIES: A  LABORA­
TORY MANUAL (Cold Spring Harbor Laboratory Press, 
1988); methods and materials relating to cytometry may be 
found in Robinson et a l, CURRENT PROTOCOLS IN 
CYTOMETRY (John Wiley & Sons, Inc, 2004).
[0053] As used herein, the term “target gene” means a 
gene or nucleic acid sequence derived from a cell or a virus 
(such as, an endogenous gene or sequence), an exogenous 
gene or sequence (such as, a gene, allele, or sequence not 
typically present in the genome), a transgene or transgenic 
sequence (such as, a gene construct or sequence introduced 
into the cell, either integrated or extrachromosomally), or a 
gene or a sequence from a pathogen which is capable o f  
infecting an organism from which the cell is derived. A  
target gene may include more than one nucleic acid 
sequence, for example, a target gene may include one or 
more members of a gene family or subfamily, for example, 
a target gene may be one or more members o f a previously 
unidentified gene family. Likewise, a taiget gene may 
include nucleic acid sequences, such as pseudogenes, iso­
forms, and/or splice variants.
[0054] Inhibition o f gene expression refers to the observ­
able decrease in the level o f protein and/or RNA product 
(gene product) from a taiget gene. Targeted inhibition refers 
to the ability to inhibit the taiget gene without manifest 
effects on other genes o f the cell. Inhibition can be measured 
by methods well known in the art. For example, RNAi 
inhibition in a cell line or whole organism may be assayed 
by use o f a reporter or other assayable marker (e .g , a drug 
resistance gene). Such reporter genes or assays are well 
known in the art.
[0055] Depending on the assay, quantification of the 
amount o f gene expression allows one to determine a degree
o f inhibition. Quantification o f gene expression in a cell may 
show inhibition o f target mRNA or translation o f taiget 
protein. For example, a gene product mRNA may be 
detected with a hybridization probe, or translated polypep­
tide may be detected with an antibody raised against the 
polypeptide sequence.
[0056] In an exemplary embodiment, the nucleic acid o f  
the invention is a vector. The vectors o f the invention may 
be one or more nucleic acids (for example, nucleic acids 
capable o f homologous recombination or Cre/Lox mediated 
recombination). The sequence o f interest may be transiently, 
conditionally or constitutively expressed. Further, chromo­
somally integrated vectors can produce a stably transformed 
or transfected cell line. Vectors for forming such stable cell 
lines include, without limitation, those described in U.S. Pat. 
No. 6,025,192 and PCT publication WO/9812339.
[0057] Promoters may be incorporated into a nucleic acid 
or vector of the invention as a means to initiate transcription. 
Suitable promoters include any nucleotide sequence capable 
o f initiating transcription under appropriate conditions. Suit­
able promoters include, without limitation, polIII promoters; 
polll promoters (see Paddison et al. (2002), Stable suppres­
sion o f gene expression by RNAi in mammalian cells, Proc. 
Natl. Acad. Sci. U.S.A. 99:1443), such as the Gal4 promoter, 
let858, SERCA, UL6, myo-2 ormyo-3, Gal4p binding sites 
and/or Pho5; poll promoters; viral promoters, such as T7, 
T3, and SP6, adenoviral promoters, the cytomegalovirus 
immediate early promoter, and the major operator and/or 
promoter regions o f phage X; yeast mating factor promoters 
(a or a); those disclosed in U.S. Pat. No. 6,537,786, the 
polyhedron or plO promoter o f the baculovirus system and 
other sequences known to control the expression o f genes 
and any combination thereof. A  person of ordinary skill in 
the art may use any known or discovered promoter in 
combination with the invention. Promoters may be, for 
example, minimal, inducible, constitutive, tissue-specific, 
rheostatic, stress-responsive, or combinations thereof.
[0058] Inducible promoters are promoters that initiate 
increased levels o f transcription from DNA to which they 
are operably linked in response to some change in cellular 
conditions, for example, the presence or absence o f a 
nutrient or a change in temperature. Inducible promoters 
(tet, hormone receptors, and so on) may be used to, for 
example, facilitate gene-silencing analyses by allowing the 
temporary suppression o f normally lethal knockouts (e .g , 
“essential genes”) and aid in dissecting the sequential or 
temporal constraints o f certain cellular phenomena. Further­
more, inducible vectors may be used, for example, to induce 
expression of the sequence of interest at a desirable time. For 
example, the sequence of interest may be under the control 
o f a promoter derived from a gene up-regulated in response 
to infection (e .g , Myb-type transcription factor, a late 
embryogenesis-abundant protein, a root-specific gene (i.e., 
TobRB7), D-ribulose 5-phosphate 3-epimerase, or a 20S 
proteasome a-subunit) by a pest or virus, thereby inducing 
expression of the dsRNA in response to infection. Inducible 
promoters are known by persons o f ordinary skill in the art.
[0059] The cell having the target gene may be derived 
from any organism. Such organisms include a plant, animal, 
protozoan, bacterium, virus, or fungus. The plant may be a 
monocot, dicot or gymnosperm; the animal may be a ver­
tebrate or invertebrate. Fungi include organisms in both the
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mold and yeast morphologies. In an exemplary embodiment, 
the invention relates to the use o f the method for the study 
o f mammalian cells, such as primary cells and lymphocytes.
[0060] There are several methods available for cell trans­
fection and transformation. For example, cells may be 
transfected by methods including, but not limited to, calcium 
phosphate, DEAE-dextran, cationic polymers, cationic den- 
drimer, viral methods, particle bombardment, hydrodynamic 
and cationic lipids. The method o f transfection or transfor­
mation is not critical to the invention and may be appropri­
ately chosen by a person of ordinary skill in the art. For 
examples o f transfection and transformation methods and 
materials see Bonifacino et a l, CURRENT PROTOCOLS 
IN CYTOMETRY (John Wiley & Sons, Inc, 2004).
EXAMPLE I
[0061] A  plasmid, pHYPER, was constructed by inserting 
the polIII HI promoter into a 5' EcoRI site and 3' Bglll site 
o f pMACS-K/k.II (Miltenyi Biotech.).
[0062] A  shRNA sequence targeted to the 5'UTR of the 
Radi 7 mRNA (Zou et al. (2002), Regulation o f ATR sub­
strate selection by Radl7-dependent loading o f Rad9 com­
plexes onto chromatin, Genes Dev. 16(2): 198-208) was 
designed. This RNAi target sequence was incorporated into 
the hairpin sequence to be expressed from the HI promoter 
(FIG. 1). The HI promoter was cloned into pMACS-K/k.II 
so that shRNAs could be expressed in transfected cells. 
Next, an oligonucleotide duplex encoding for an RNA 
hairpin sequence targeting the 5' untranslated region o f the 
Radi 7 mRNA (Zou, Cortez et al. 2002) was inserted down­
stream o f the HI promoter (FIG. 1), using 5' Bglll and 3' 
Hindlll sites.
[0063] Cell Culture and Transfection: HeLa cells were 
cultured in DMEM supplemented with 10% FBS and 1% 
PSG at 37° C , 5% C 02. Plasmid DNA was transfected 
using 10 |xg DNA/107 cells at ooQ, 975 mF, 310 V. Cells were 
re-cultured in fresh media for 24 hours post-transfection.
[0064] Magnetic Sorting and Flow Cytometry: Cells were 
detached using 2 mM EDTA in PBS 24 hours after trans­
fection. These cells were then incubated with a-K/k.II 
conjugated magnetic beads at a concentration o f 10 |xl 
beads/10 cells for 15 minutes and washed with MACS 
buffer (lxPBS, 0.5% BSA, 2 mM EDTA). Approximately 
10 cells were taken and incubated with a-K/k.II-FITC 
antibody at a concentration o f 1:200 in FACS buffer ( lx  
PBS, 2% fetal bovine serum, 0.5 mM EDTA) for ten 
minutes, washed with FACS buffer, fixed with 2% paraform­
aldehyde in PBS and analyzed for transfection efficiency by 
one-color flow cytometry. The remainder o f the magnetic 
bead-bound cells were sorted using the double-positive 
selection program on an autoMACS magnetic cell sorter 
(Miltenyi Biotech.). The cells positive for expression o f the 
separation marker were put back into culture and allowed to 
recover for 24 hours. Approximately 105 o f the positive cells 
were incubated with a-K/k.II-FITC antibody as described 
above for flow cytometric analysis o f sorting efficiency.
[0065] Hela cells were transfected with pMACS-K/k-Hl- 
Radl7 and pMACS-K/k-Hl by electroporation. Twenty- 
four hours after transfection, the cells were detached, incu­
bated with a-K/k.II magnetic beads and sorted by 
autoMACS. Fractions o f the cell populations before and
after sorting were incubated with a-K/k.II-FITC antibody 
for analysis o f transfection and autoMACS sorting efficien­
cies by flow cytometry. One-color flow cytometry showed 
that initial transfection efficiencies o f 49% and 42% for 
pMACS-K/k-Hl and pMACS-K/k-Hl-Radl7 were 
achieved, respectively, when compared to a mock trans­
fected control (FIG. 1). Analysis o f the positively sorted cell 
population showed the high purity o f our positively selected 
cell population. The post-sort population o f pMACS-K/k- 
H1 transfected cells was 97% pure for K/k.II expression 
(FIG. 2). 98% o f the positively sorted population o f 
pMACS-K/k-Hl-Radl7 transfected cells expressed K/k.II 
and presumably shRNA directed at Radl7 mRNA (FIG. 2).
[0066] Western Blotting: Cells were harvested 24 and 48 
hours after autoMACS sorting and resuspended in Laem- 
mli’s Buffer at a concentration o f 106 cells/200 jxl. Samples 
were boiled and electrophoretically separated on a 10% 
SDS-polyacrylamide gel. Protein was transferred to PVDF 
membrane (Amersham) using a semi-dry transfer system 
(Bio-Rad). Blots were blocked in 5% skim milk in TPBS for 
one hour. Primary a-R adl7 antibody (Santa Cruz) was used 
at 1:500. Secondary goat a-rabbit IgG conjugated to horse­
radish peroxidase (Santa Cruz) was applied at 1:1000. Blots 
were developed using an enhanced chemiluminescence kit 
(Amersham).
[0067] In order to confirm mRNA translation suppression 
indicative o f successfixl RNA interference, cellular levels o f 
Radi 7 protein were quantified. Cells from the pMACS-K/ 
k-Hl and pMACS-K/k-Hl-Radl7 positive populations were 
harvested at 48 and 72 hours post-transfection for Western 
Blotting. Our results indicate that the pMACS-K/k-Hl- 
Radl7 plasmid expressing Radi 7-specific shRNAs signifi­
cantly reduced cellular Radi 7 protein levels up to 72 hours 
after plasmid transfection (FIG. 3). Importantly, Radl7 
levels were reduced relative to the pMACS-K/k-Hl trans­
fected control, showing that Radi 7 knock-down was attrib­
utable to shRNA expression (FIG. 3).
EXAMPLE II
[0068] A plasmid expressing enhanced green fluorescence 
protein (EGFP) or a variant thereof is constructed wherein 
expression o f EGFP is driven by a constitutive promoter 
recognized by the host cell. In addition, a tetracycline- 
inducible promoter system (tet system) is operably linked to 
an inverted repeat sequence (shRNA) with stem sequences 
complementary to a mRNA sequence derived from the gene 
o f interest, for example, hoxbl3.
[0069] For example, a sequence from the gene of interest 
(e.g., hoxbl3; ccaggagctc cctgaaaccc (SEQ ID NO:3)), a 
loop sequence (e.g., a six to nine nucleotide loop sequence), 
the complement o f the sequence from the gene o f interest 
(e.g., gggtttcagg gagctcctgg (SEQ ID NO:4)), and transcrip­
tional terminator are operably linked to the tet promoter. 
Thus, the tet promoter is operably linked to provide induc­
ible expression o f the small hairpin RNA of hoxbl3. Thus, 
a shRNA is encoded by the tet system.
[0070] The tet promoter is well known in the art. The 
tetracycline-dependent regulatory system (tet system) is 
based upon the interaction between the tetracycline trans­
activator (tTA), consisting o f the prokaryotic TetR fused to 
the activator domain of the herpes simplex virus VP 16 
protein, and the tetracycline-responsive element (TRE), con­
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sisting o f seven copies o f the prokaryotic tetracycline opera­
tor site (tetO) fused to a minimal CMV promoter. In the 
presence o f tetracycline (tet), tTA loses its ability to bind the 
TRE and expression is shut off.
[0071] The tet system shRNA and EGFP expression sys­
tem is transfected into primary neuronal cells. The cells are 
cultured in the presence o f tet, allowing recovery and 
expression o f the selection marker, but preventing expres­
sion o f the shRNA, and the cells are then separated by flow 
cytometry. The sorted cells, expressing EGFP, are then 
assayed for effect o f the siRNA, for example, by culture in 
the absence o f tet, to determine if  hoxbl3 may act as an 
inhibitor o f neuronal cell proliferation. The sorted cells may 
be split into two pools, those expressing EGFP and those 
lacking EGFP, and compared, wherein the cells lacking 
EGFP may serve as a control. In another embodiment, cells 
expressing EGFP but without the shRNA may be used as a 
control.
EXAMPLE III
[0072] An inverted repeat operably linked to an RNA 
polymerase III (polIII) promoter o f the U6 small nuclear 
RNA gene (U6) is constructed. The U6 driven inverted 
repeat and a selection marker (e.g., the ABC transporter gene 
MDR 1) are cloned into a nucleic acid sequence. The nucleic 
acid sequence is packaged in vitro using four recombinant 
SV40 proteins (VP1, VP2, VP3, and agno) or VP1 only 
(Kimchi-Sarfaty et al. (2003), High Cloning Capacity o f In 
Vitro Packaged SV40 Vectors with No SV40 Virus 
Sequences, Hum. Gene Ther. 14(2):167-177). The in vitro 
packaged SV40 is infected into host cells.
[0073] Antibodies specific to the transporter are used to 
detect cell surface expression and cells expressing the trans­
porter are sorted by fluorescence-activated cell sorter analy­
sis (FACS). Sorted cells, expressing the selection marker are 
assayed for the effect o f gene silencing by the inverted repeat 
sequence.
[0074] A  library o f siRNA producing plasmids are created 
using Lox/cre mediated recombination. For example, to 
overcome the cell type limitation imposed by a retroviral 
construct, a library o f shRNA sequences, such as those o f 
Paddison et al. (2004), are transferred to a plasmid o f the 
invention. F IG . 4 illustrates a method o f transferring a 
library o f shRNA sequences, such as those of Paddison et al.
(2004), to a plasmid o f the present invention.
[0075] The library o f shRNA sequences are transformed 
into 5x108 cells and sorted using an auto MACS magnetic 
cell sorter (Miltenyi Biotech.) as described herein. The cells 
positive for expression o f the separation marker are put back 
into culture and allowed to recover for 24 hours. The 
positive cells are then screened for a desired activity.
[0076] Alternatively, a separation marker may be intro­
duced into the retroviral vector, for example, the retroviral 
vector o f Paddison et al. (2004), allowing separation o f 
infected from non-infected cells. Such a method may allow 
the use of a lower multiplicity o f infection and/or reduce 
undesirable background.
[0077] All references, including publications, patents, and 
patent applications, cited herein are hereby incorporated by 
reference to the same extent as if  each reference were 
individually and specifically indicated to be incorporated by 
reference and were set forth in its entirety herein.
[0078] While this invention has been described in certain 
embodiments, the present invention can be further modified 
within the spirit and scope o f this disclosure. This applica­
tion is therefore intended to cover any variations, uses, or 
adaptations o f the invention using its general principles. 
Further, this application is intended to cover such departures 
from the present disclosure as come within known or 
customary practice in the art to which this invention pertains 
and which fall within the limits o f the appended claims.
EXAMPLE IV
SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 4
<210> SEQ ID NO 1
<2 11> LENGTH: 64
<212> TYPE: DNA
<213> ORGANISM: A rtific ia l
<220> FEATURE:
<223> OTHER INFORMATION: top s trand  of the Rad 17 shRNA sequence
<400> SEQUENCE: 1
gatcccccag ac tggg ttga  c c c a tc ttc a  agagagatgg gtcaacccag t c t g t t t t t g  60
gaaa 64
<210> SEQ ID NO 2
<2 11> LENGTH: 64
<212> TYPE: DNA
<213> ORGANISM: A rtific ia l
<220> FEATURE:
<223> OTHER INFORMATION: Complementary s trand  shown as th e  bottom 
stran d  of figure 1
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- c o n t i n u e d
<400> SEQUENCE: 2
tcgaaaaggt t t t t g t c t g a  cccaactggg tagagagaac ttc ta c c c a g  ttg gg tcaga  60
<210> SEQ ID NO 3
<2 11> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 3
ccaggagctc cctgaaaccc
<210> SEQ ID NO 4
<2 11> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: A rtific ia l
<220> FEATURE:
<223> OTHER INFORMATION: Complement of th e  hoxbl3 sequence
<400> SEQUENCE: 4 
gggtttcagg  gagctcctgg
64
1. A  method o f obtaining cells capable o f expressing 
inhibitory RNA, the method comprising:
introducing at least one nucleic acid into a cell, wherein 
the at least one nucleic acid is able to express an RNAi 
molecule and a separation marker;
expressing a separation marker;
sorting the cell based on expression of the separation 
marker; and
expressing the RNAi molecule in an amount sufficient to 
inhibit expression of the target gene.
2. The method according to claim 1, wherein the RNAi 
molecule is a taiget gene selected from the group consisting 
o f a cellular gene, an endogenous gene, a transgene and a 
viral gene.
3. The method according to claim 1, wherein the cell is o f  
mammalian or plant origin.
4. The method according to claim 1, wherein sorting the 
cell comprises fluorescence activated cell sorting.
5. The method according to claim 1, wherein sorting the 
cell comprises magnetic cell separation.
6. The method according to claim 1, wherein introducing 
the at least one nucleic acid into the cell comprises intro­
ducing the at least one nucleic acid into less than 50% of the 
cells.
7. The method according to claim 1, wherein introducing 
at least one nucleic acid into a cell comprises introducing a 
library o f RNAi molecules.
8. Amethod o f enriching a population o f mammalian cells 
having an inhibitory RNA sequence, the method comprising:
providing mammalian cells containing a target gene, 
wherein target cells are susceptible to RNA interfer­
ence, and the taiget gene is expressed in the target cells;
introducing in the mammalian cells an RNA molecule, 
wherein the RNA molecule may produce RNA inter­
ference and contains a double-stranded area with a first 
region having a sequence which corresponds to a 
nucleotide sequence of the taiget gene and a second 
region having a sequence which is complementary to 
the first region, wherein the first and the second regions 
hybridize to each other to form a double-stranded RNA 
molecule;
introducing in the mammalian cells a separation marker;
expressing the separation marker in the mammalian cells, 
wherein expression o f the separation marker is indica­
tive of the presence of the double-stranded RNA mol­
ecule; and
sorting the mammalian cells expressing the separation 
marker, thereby enriching for the mammalian cells 
having the double-stranded RNA sequence.
9. The method according to claim 8, wherein the mam­
malian cells are o f human origin.
10. The method according to claim 7 or claim 8, wherein 
the mammalian cells are primary cells.
11. he method according to claim 8, wherein the double­
stranded ribonucleic acid structure is at least 18 bases in 
length and each o f the ribonucleic acid strands is able to 
specifically hybridize to a deoxyribonucleic acid strand o f 
the target gene over the at least 18 bases.
12. The method according to claim 10, further comprising 
inhibiting expression o f the target gene by at least 10%.
13. The method according to claim 8, further comprising 
transfecting the mammalian cells with a first nucleotide 
sequence encoding the separation marker and a second 
nucleotide sequence capable o f producing the RNA mol­
ecule.
14. The method according to claim 12, wherein transfect­
ing the mammalian cells produces less than 40% of the 
mammalian cells expressing the separation marker.
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15. A  recombinant nucleic acid sequence comprising at 
least one nucleic acid sequence, wherein the at least one 
nucleic acid sequence is capable o f expressing a separation 
marker and the at least one nucleic acid sequence comprises 
a promoter operably linked to a sequence capable o f pro­
ducing an inhibitor RNA, wherein the inhibitor RNA com­
prises a sequence complementary to a target gene.
16. The recombinant nucleic acid sequence o f claim 15, 
wherein the inhibitor RNA comprises a first region which is 
complementary to the target gene and a second region which 
is complementary to the first region, wherein the inhibitor 
RNA is capable o f forming a short hairpin RNA.
17. The recombinant nucleic acid sequence o f claim 15, 
wherein the separation marker and the sequence capable o f  
producing the inhibitor RNA are on the same nucleic acid 
molecule.
18. The recombinant nucleic acid sequence o f claim 17, 
wherein the at least one nucleic acid is a vector.
19. The recombinant nucleic acid sequence o f claim 18, 
wherein the vector comprises pHYPER.
20. The recombinant nucleic acid sequence o f claim 15, 
wherein the separation marker is recognized by an antibody.
21. The recombinant nucleic acid sequence o f claim 20, 
wherein the antibody is coupled to a label, the label selected 
from the group consisting o f a magnetic reagent, a fluores­
cent molecule, an enzyme, and combinations of any thereof.
22. The recombinant nucleic acid sequence o f claim 15, 
wherein the promoter is a type III DNA dependent RNA 
polymerase promoter.
23. The recombinant nucleic acid sequence o f claim 15, 
wherein the inhibitor RNA comprises a library o f sequences 
capable o f forming a short hairpin RNA.
24. A  cell comprising the recombinant nucleic acid 
sequence of claim 15.
25. A  recombinant nucleic acid sequence comprising:
at least one nucleic acid sequence having means for 
producing a separation marker and means for produc­
ing a ribonucleic acid sequence which is able to inhibit 
translation o f a target gene.
